This readout extends the ivonescimab clinical narrative beyond NSCLC, de-risking the platform for other solid tumor indications. Traders should watch for detailed data at the upcoming medical congress and any regulatory path commentary for BTC in Summit's territories. The BLA for HARMONi (EGFR-mutated NSCLC) has a PDUFA date of November 14, 2026, which remains the near-term catalyst.
Price Chart
Executive Summary
Partner Akeso announced positive topline results from the Phase III HARMONi-GI1 study evaluating ivonescimab plus chemotherapy in first-line advanced biliary tract cancer (BTC), achieving statistically significant overall survival (OS) superiority vs. durvalumab plus chemotherapy, along with meeting key secondary endpoints of PFS and ORR. This marks the first Phase III ivonescimab readout beyond NSCLC and the fifth positive Phase III readout overall for the program. Detailed data expected at a future medical congress — the filing is a clinical milestone update with no financial figures or regulatory actions in Summit's territories.
Key Facts
- Partner Akeso reported positive topline results from randomized Phase III HARMONi-GI1 study (AK112-309) in first-line advanced biliary tract cancer (BTC).
- Ivonescimab + chemotherapy achieved statistically significant and clinically meaningful OS superiority vs. durvalumab + chemotherapy at pre-specified interim analysis.
- Study also met key secondary endpoints of progression-free survival (PFS) and objective response rate (ORR).
- HARMONi-GI1 is the first Phase III ivonescimab readout outside of NSCLC, and is the fifth positive Phase III readout for ivonescimab overall.
- The study was conducted solely in China by Akeso; ivonescimab remains investigational in Summit's license territories (U.S., Europe, etc.).
- Detailed safety and efficacy data are expected to be presented at an upcoming medical congress and published in a peer-reviewed journal.
Financial Impact
No financial figures provided; this is a clinical milestone with potential to expand ivonescimab's addressable market into BTC.
Risk Factors
- HARMONi-GI1 was a single-region China-only study; results may not be fully generalizable to global populations.
- No BTC regulatory filings or timelines have been announced in Summit's license territories.
- Detailed safety and efficacy data are not yet available; the magnitude of OS benefit is undisclosed.
- Ivonescimab is not approved in any of Summit's license territories.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001599298-26-000074 |
| Document: 0001599298-26-000074-index.html | 0001599298-26-000074 |
| Document: 0001599298-26-000074.txt | 0001599298-26-000074 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $17.40 $17.85 | ▲ +2.59% | ▲ +1.77% | $16.75 (−3.71%) |
Sep 14, 2026 18d ago | 8-K | $18.42 $16.90 | ▼ −8.25% | ▼ −8.36% | $16.75 (−9.04%) |
Sep 3, 2026 29d ago | 8-K | $17.13 $17.55 | ▲ +2.45% | ▲ +3.60% | $16.75 (−2.19%) |
Aug 26, 2026 5w ago | 8-K | $14.23 $14.60 | ▲ +2.60% | ▲ +2.72% | $16.75 (+17.74%) |
Aug 5, 2026 8w ago | 8-K | $13.53 $15.10 | ▲ +11.60% | ▲ +11.25% | $16.75 (+23.84%) |
Jul 22, 2026 10w ago | 8-K | $14.74 $12.80 | ▼ −13.16% | ▼ −10.76% | $16.75 (+13.67%) |
Jun 12, 2026 16w ago | Insider Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.01 $13.75 | ▼ −1.86% | ▼ −2.53% | $16.75 (+19.59%) |
Jun 11, 2026 16w ago | Institutional Cluster | $13.08 $14.07 | ▲ +7.57% | ▲ +7.14% | $16.75 (+28.10%) |
Jun 9, 2026 16w ago | S-3ASR | $13.05 $13.88 | ▼ −6.36% | ▼ −2.93% | $16.75 (−28.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access